SHARE
COPY LINK

ALZHEIMERS

Lab results back caffeine benefit on Alzheimer’s

French and German researchers on Wednesday said they had found evidence in the lab to back theories that drinking caffeine has a preventive effect on Alzheimer's disease.

Lab results back caffeine benefit on Alzheimer's
Lab results back theory that drinking coffee can help prevent Alzheimers. Photo: Scott Feldstein/AFP

In mice, regular doses of caffeine inhibited the growth of tau, a protein that clogs brain cells in Alzheimer's patients, they said.

The discovery was made among mice that had been genetically modified to produce tau.

They were given a tiny dose of caffeine – 0.3 grammes per litre (0.005 ounces per pint) – in their drinking water over 10 months.

This is roughly equivalent to two cups of coffee per day for human beings.

The mice were compared with an identical group of "tau" rodents which did not get the caffeine dose.

"Mice that were given caffeine were less affected in terms of memory and tau buildup but also in terms of inflammation of the brain tissue," said David Blum of France's National Institute of Health and Medical Research (Inserm).

Previous research has found that older people are less likely to suffer cognitive decline if they take regular, moderate amounts of caffeine.

Experiments have also found that caffeine slows memory loss in mice bred to develop so-called amyloid plaques – another compound buildup in the brain that is associated with Alzheimer's.

The study appears in the US journal Neurobiology of Aging.

Member comments

Log in here to leave a comment.
Become a Member to leave a comment.

ALZHEIMERS

Swiss firms team up to develop Alzheimer’s test

Swiss firms Nestlé Institute of Health Sciences (NIHS) and AC Immune, a biopharmaceutical company, announced on Wednesday a new partnership to develop an early Alzheimer's diagnostic test.

Swiss firms team up to develop Alzheimer's test
A Nestlé unit is teaming up with another Swiss firm on the Alzheimer's test. Photo: AFP

According to an AC Immune statement, the goal of the research collaboration is to develop a “minimally invasive diagnostic test to identify patients at very early stages.”
   
AC Immune's communications manager Eva Schier said the goal is to test for Alzheimer's by using a blood sample.
   
The sample could potentially show traces of neurofibrillary tangles, of which the chief component is a protein called Tau.

“Tau tangles” are one of the major indicators of Alzheimer's disease.
   
“It has been impossible to detect Tau in the blood,” Schier told AFP, adding that with the proper technology lab tests could help identify the initial biological signs of the disease.
   
Schier said that the research is still in its “very early” stages.
   
According to the statement, AC Immune will provide its “world leading expertise in the biology and pathology of Tau” as well as “laboratory capabilities.”
   
NIHS, a division of Vevey-based Nestlé, will for its part provide a “technology platform to the research program” to help identify Tau in blood plasma and cerebrospinal fluid (CSF).
   
NIHS director Professor Ed Baetge said that the “overarching goal is to develop nutritional approaches and technologies that help people maintain or re-establish their cognitive vigour.”
   
A new case of Alzheimer's is diagnosed in the world every three seconds, and 46.8 million people were affected by the disease as of 2015.

Global patient numbers are expected to increase to 131.5 million by 2050, according to AC Immune.
   
Professor Andrea Pfeifer, CEO of AC Immune, says that early detection is “needed for the development of pharmaceutical as well as nutritional approaches.”
   
Schier says that the early detection should also benefit patients in other ways.
   
“The earlier you start treating patients (with Alzheimer's), the better it is,” she said.
   
“Usually, the patient goes to the doctor when they already have problems. In an ideal world one could treat patients who don't have symptoms yet.”
   
According to the statement, the new partnership is AC Immune's fourth involving the Tau protein.

Financial details of the collaboration with NIHS were not disclosed.

SHOW COMMENTS